Kirenga, Bruce J.
Mugenyi, Levicatus http://orcid.org/0000-0002-9423-2472
Sánchez-Rico, Marina http://orcid.org/0000-0002-1121-8641
Kyobe, Henry http://orcid.org/0000-0001-6593-8727
Muttamba, Winters
Mugume, Raymond
Mwesigwa, Eliya
Kalimo, Ezra
Nyombi, Vicky
Segawa, Ivan http://orcid.org/0000-0002-4535-1694
Namakula, Loryndah Olive
Sekibira, Rogers
Kabweru, Wilberforce
Byanyima, Rosemary
Aanyu, Hellen http://orcid.org/0000-0003-3159-4318
Byakika-Kibwika, Pauline http://orcid.org/0000-0003-0757-1968
Mwebesa, Henry G.
Hoertel, Nicolas
Bazeyo, William
Funding for this research was provided by:
Government of Uganda through Makerere University Research and Innovations Fund
Article History
Received: 17 November 2022
Revised: 8 February 2023
Accepted: 15 February 2023
First Online: 3 March 2023
Competing interests
: NH is an inventor on a patent application related to methods of treating COVID-19 (FIASMA antidepressants), filled by Assistance Publique-Hopitaux de Paris in France. The other authors have no conflicts of interest related to this work to declare.
: Compassionate use approval of fluvoxamine for the treatment of COVID-19 was obtained from the Ministry of Health of Uganda (clearance reference no. ADM.180/O1 dated 2nd January 2022). All patients were informed that this medication was under evaluation by health authorities. Patients willing to be treated with this medication gave verbal informed consent. All data used in this study were collected as part of routine care.